Written Question · S2W-29093 · Session 2
Whether it will undertake a study to compare the outcomes for patients who purchase donepezil, galantamine and rivastigmine privately for m…
The question
To ask the Scottish Executive whether it will undertake a study to compare the outcomes for patients who purchase donepezil, galantamine and rivastigmine privately for mild Alzheimer’s disease and patients who do not receive the drug until they develop moderate Alzheimer’s disease.
The answer
The Chief Scientist Office (CSO),within the Scottish Executive Health Department, has responsibility for encouragingand supporting research into health and health care needs in Scotland. TheCSO does not normally commission research but supports research projects of a sufficientlyhigh standard initiated by the research communityin Scotland. This role is well known and advertised throughout thehealth care and academic community in Scotland. Although the CSO is not directly funding any researchinto anticholinesterase inhibitors, donepezil, galantamine or rivastigmine, it wouldbe pleased to consider proposals for research into Alzheimer’s disease which wouldbe subject to the usual peer and committee review.
The Medical Research Council,one of the main agencies through which the UK Government supports medical and clinicalresearch, currently supports two trials looking at the efficacy of anticholinesteraseinhibitors in the treatment of patient groups with moderate to severe Alzheimer’sdisease.
The Medical Research Council,one of the main agencies through which the UK Government supports medical and clinicalresearch, currently supports two trials looking at the efficacy of anticholinesteraseinhibitors in the treatment of patient groups with moderate to severe Alzheimer’sdisease.
In the Official Report
No contribution in the Official Report cites S2W-29093 by reference.